Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 3.3M | 64.7% |
| Gross Profit | 1.9M | 250.9% |
| Cost of Revenue | 1.4M | 58.2% |
| Operating expense | 35M | 29.5% |
| Net Income | -32M | 13.2% |
| EBITDA | -32M | 13.4% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 252M | 34.7% |
| Total Liabilities | 21M | 10% |
| Total Equity | 231M | 37.6% |
| Shares Outstanding | 8.9M | 21.8% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -29M | 94% |
| Cash from investing | -960,000 | 62.1% |
| Cash from financing | 95M | 762.9% |
EPS
Financial Highlights for Tonix Pharmaceuticals in Q3 '25
Tonix Pharmaceuticals reported a revenue of 3.3M, which is a 64.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.9M, marking a 250.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.4M, a -58.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 35M, showing a 29.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -32M, showing a -13.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -32M, showing a -13.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Tonix Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
